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Abstract Statement of the Problem
• Current treatments for OA such as weight loss, physical therapy, 
and pharmaceuticals help lessen the pain and increase mobility in 
cases of mild to moderate OA. In severe cases, the standard of 
care in the U.S. is TKA. Although effective in most cases, the 
procedure itself is invasive, has the potential for failure and 




• Healthy articular cartilage protects and provides smooth 
functioning of the joint. The deterioration of the articular cartilage 
leads to the crippling disease known as osteoarthritis (OA). 
• OA is a leading cause of disability in the United States. Although 
some of the current treatment modalities, along with 
pharmacological treatment, may offer short term improvement 
with pain and function, they do not offer long term relief, and are 
ineffective in preventing the progression of OA. 
• In advanced stages, surgery in the form of total knee arthroplasty 
(TKA), is sometimes needed. This is an invasive procedure and 
typically requires hospitalization.
• Now, there is a safe and effective modality on the horizon. This 
minimally invasive treatment is the injection of mesenchymal stem 
cells (MSCs) directly into the affected joint. 
• These are multipotent progenitor cells that offer 
immunosuppressive and anti-inflammatory action, have the 
capacity of self-renewal, and have high plasticity. MSCs can be 
harvested from the patient themselves, autologous, or can be from 
a donor, allogeneic.
• A review of the literature suggests treatment of moderate to severe 
OA  of the knee with MSC injections are a viable treatment option 
when compared to other treatments that include a total knee 
replacement. MSC s are the only treatment option that have 
evidence of cartilage regeneration in addition to improvement of 
functional mobility, pain relief, and overall improvement in quality 
of life. 
Pathophysiology of osteoarthritis:
• Proper, non-painful joint function in the human body is dependent 
upon the wellness of the articular cartilage that covers the 
opposing articulating bones. Deterioration of the articular cartilage 
leads to the crippling disease known as OA (Correa and Lietman, 
in press).
• Patients with OA experience loss of flexibility, stiffness, swelling 
and pain, leading to loss of mobility which leads to weight gain, 
which is worse on OA affected joints (Burke et al. 2016).
• OA also involves structures such as subchondrial bone, synovial 
fluid, and the synovial membrane, causes hypertrophic bone 
changes with osteophyte formation and subchondrial bone 
remodeling (Pearle et al. 2005).
Current treatments for osteoarthritis:
• Aquatic exercises improved pain symptoms, but only for a short 
term following conclusion of treatment (Bartels et al. 2016).
• Land based physical therapy results in pain reduction and 
improved function and quality of life for up to 6 months following 
the completion of the program (Fransen et al.2015).
• Intra-articular corticosteroid injections showed improvement with 
function for up to 6 weeks and pain relief for up to 13 weeks post 
injection (Jüni et al. 2015).
• Viscosupplementation injection in the knee with hyaluronan 
showed significant improvement with pain and function up to 13 
weeks post injection (Bellamy et al. 2005).
 Total knee arthtoplasty (TKA) leads to reduction in pain, 
improvement of function, and better quality of life for treatment of 
severe OA (Singh et al. 2013).
Mesenchymal stem cells for treatment of osteoarthritis:
 Recent evidence suggests that MSC injection can boost repair and 
limit further destruction of joint (Diekman and Guilak, 2013).
 MSC injection significantly improves cartilage quality resulting in 
pain relief and improved quality of life (Mehrabani et al. 2016).
 MSC sheet implantation show greater efficacy over MSC injections 
in promoting meniscus regeneration while inhibiting progression 
of OA (Qi et al. 2016).
• Clinicians are taught to always have their patients best interest in 
mind. For treatment of OA, there are many different conservative 
choices such as land and water exercise therapy, electromagnetic 
therapy, oral pain medications, and injectable steroids to name a 
few, that are non-invasive and inexpensive, however, they each 
have a varying degree of success with pain control, functional 
improvement, and improvement in quality of life, but none show 
regenerative properties for the cartilage that is damaged. 
• Based on moderate quality of evidence, treatment of OA, mostly in 
the knee, with mesenchymal stem cell injections, are the only 
option that show regeneration of cartilage. This leads to 
improvement of functional mobility, pain relief, and overall 
improvement in quality of life. 
• When compared to a TKA, which is the current standard of care for 
severe OA, it is minimally invasive, less painful, has minimal 
associated risks, requires less rehabilitation time, and causes a lower 
burden of cost on the health care system.   
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Introduction
• Osteoarthritis (OA) is a leading cause of joint disease characterized 
by the degeneration of articular cartilage. OA leads to pain, 
stiffness, swelling, tenderness, and loss of mobility and flexibility 
in the affected joint. These symptoms lead to reduced activity, 
which leads to weight gain, which worsens OA. (Burke, et al. 
2016). There is no cure for this disease. 
• Most treatments are short lived, and only offer little relief. For 
severe OA, surgical treatment, such as total knee arthroplasty 
(TKA), may offer longer relief, however, this procedure is invasive, 
requires hospitalization, causes moderate to severe pain, and has 
risks for infection and failure.  
• According to new research, a promising treatment could be on the 
horizon.
• The newest treatment that is being researched for the treatment of 
moderate to severe OA is mesenchymal stem cell injections. 
When compared to TKA surgery, this treatment is much less 
invasive, has a much quicker recovery time, less chance for 
adverse events, and is much less expensive
Applicability to Clinical
Practice
• In patients with moderate to severe osteoarthritis, could 
mesenchymal stem cell injections, compared to current 
treatments, offer longer pain relief and improved function?
• In patients with severe osteoarthritis, is treatment with 
mesenchymal stem cells, compared to total knee arthroplasty, less 
expensive? 
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Treatment sample size improvement ≥ 8 weeks improvement  ≥ 12 weeks improvement  ≥ 6 months improvement ≥ 12 months
hyaluronan or hylan 
derivatives (HA)
76 trials yes yes no no
TKA (total knee arthroplasty) 122 patients yes yes yes yes
electromagnetic field 
treatment
636 patients no no no no
therapeutic ultrasound 341 patients yes no no no
corticosteroid injection 1767 patients no no no no
land based exercise 3913 patients yes yes yes no
Mesenchymal Stem Cell 
(MSC) injection low dose
30 patients yes yes yes no
Mesenchymal Stem Cell 
(MSC) injection high dose
30 patients yes yes yes yes
Function and mobility improvement by treatment.
Treatment sample size improvement ≥ 8 weeks improvement  ≥ 12 weeks improvement  ≥ 6 months improvement ≥ 12 months
hyaluronan or hylan 
derivatives (HA)
76 trials yes yes no no
TKA (total knee arthroplasty) 122 patients yes yes yes yes
electromagnetic field 
treatment
636 patients yes yes no no
therapeutic ultrasound 341 patients yes no no no
corticosteroid injection 1767 patients yes yes no no
land based exercise 3913 patients yes yes yes no
Mesenchymal Stem Cell 
(MSC) injection low dose
30 patients yes yes yes no
Mesenchymal Stem Cell 
(MSC) injection high dose
30 patients yes yes yes yes
Improvement in pain by treatment.
Cont. Literature Review
Cost comparison of treatments used for osteoarthritis:
 The average cost of TKA is $49,500 for uninsured patients 
(Greengard 2015).
 MSC injections for OA is currently under research and is not 
covered by insurance. It is estimated at $3,000-$3,500 to inject one 
joint and $4,000-$5,000 for two joints (Dr. Robert J. Daley, n.d.).
